Immix Biopharma, Inc. (NASDAQ:IMMX) Given Consensus Recommendation of “Moderate Buy” by Brokerages

Immix Biopharma, Inc. (NASDAQ:IMMX) has been given a consensus rating of “Moderate Buy” by the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell rating, one has assigned a hold rating and four have given a buy rating to the company. The average twelve-month price objective among brokers that have issued a report on the stock in the last year is $19.50.

Several equities analysts have recently weighed in on IMMX shares. Wall Street Zen cut Immix Biopharma from a “hold” rating to a “sell” rating in a research report on Sunday, March 15th. Mizuho lifted their price target on Immix Biopharma from $14.00 to $15.00 and gave the company an “outperform” rating in a research report on Monday, March 30th. Morgan Stanley started coverage on Immix Biopharma in a research report on Wednesday, March 25th. They issued an “overweight” rating and a $20.00 price target for the company. Weiss Ratings reiterated a “sell (d-)” rating on shares of Immix Biopharma in a research report on Tuesday, April 21st. Finally, Citizens Jmp reiterated a “market outperform” rating and issued a $23.00 price target on shares of Immix Biopharma in a research report on Friday, March 27th.

Hedge Funds Weigh In On Immix Biopharma

Hedge funds have recently made changes to their positions in the stock. Eventide Asset Management LLC purchased a new position in shares of Immix Biopharma in the fourth quarter valued at $13,331,000. Blue Owl Capital Holdings LP purchased a new position in shares of Immix Biopharma in the fourth quarter valued at $5,158,000. Allworth Financial LP purchased a new position in Immix Biopharma during the fourth quarter worth about $30,000. Mathes Company Inc. purchased a new position in Immix Biopharma during the fourth quarter worth about $56,000. Finally, Barclays PLC purchased a new position in Immix Biopharma during the fourth quarter worth about $183,000. 11.26% of the stock is currently owned by hedge funds and other institutional investors.

Immix Biopharma Price Performance

Shares of IMMX opened at $8.74 on Wednesday. The firm has a market cap of $475.54 million, a PE ratio of -9.50 and a beta of 0.10. The stock’s fifty day moving average price is $9.20 and its two-hundred day moving average price is $7.68. Immix Biopharma has a 1 year low of $1.94 and a 1 year high of $11.61.

Immix Biopharma (NASDAQ:IMMX) last issued its earnings results on Thursday, May 7th. The company reported ($0.18) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.19) by $0.01. Sell-side analysts anticipate that Immix Biopharma will post -0.7 earnings per share for the current fiscal year.

About Immix Biopharma

Immix Biopharma (NASDAQ:IMMX) is a clinical-stage biopharmaceutical company focused on the discovery and development of novel immuno-oncology therapies that target myeloid checkpoints. The company’s approach centers on harnessing the innate immune system to promote anti-tumor activity, complementing established T-cell checkpoint inhibitors. By modulating key myeloid pathways, Immix Biopharma aims to overcome resistance mechanisms in solid tumors and broaden the scope of effective cancer immunotherapy.

The company’s lead candidate, IMX-110, is a first-in-class combination therapy designed to activate macrophages and dendritic cells within the tumor microenvironment.